

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 June 2021 (10.06.2021)



(10) International Publication Number
WO 2021/111425 A1

(51) International Patent Classification:
C07K 14/16 (2006.01) A61K 47/64 (2017.01)

(21) International Application Number:
PCT/IB2020/061590

(22) International Filing Date:
07 December 2020 (07.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/944,606 06 December 2019 (06.12.2019) US

(71) Applicant: TAVANTA THERAPEUTICS HUNGARY
INCORPORATED [HU/HU]; Madarász Viktor utca
47-49., 1138 Budapest (HU).

(72) Inventors: MÁNDITY, István; c/o Tavant Therapeu-
tics Hungary Incorporated, Madarász Viktor utca 47-49.,
1138 Budapest (HU). MALÉTH, József; c/o Tavant
Therapeutics Hungary Incorporated, Madarász Viktor utca
47-49., 1138 Budapest (HU). VARGA, Zoltán; c/o Tavan-
ta Therapeutics Hungary Incorporated, Madarász Viktor ut-
ca 47-49., 1138 Budapest (HU). VARRÓ, Nikolett; c/o Ta-
vanta Therapeutics Hungary Incorporated, Madarász Vik-
tor utca 47-49., 1138 Budapest (HU). BERECKZI-SZA-
KÁL, Dorottya; c/o Tavant Therapeutics Hungary Incor-
porated, Madarász Viktor utca 47-49., 1138 Budapest (HU).
BASA-DÉNES, Orsolya; c/o Tavant Therapeutics Hun-
gary Incorporated, Madarász Viktor utca 47-49., 1138 Bu-
dapest (HU).

(74) Agent: MOLNÁR, István; Danubia Patent & Law Office
LLC, Bajcsy-Zsilinszky út 16., 1051 Budapest (HU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: PEPTIDE-BASED SYNTHETIC CHLORIDE ION TRANSPORTERS

(57) Abstract: The present invention relates to the field of human therapy. In particular, the present invention relates to novel synthetic peptide-based chloride ion transporter and to compositions thereof, as well as methods of treating, reducing, inhibiting or controlling CFTR-mediated conditions in a subject, such as cystic fibrosis.

WO 2021/111425 A1